Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Company Overview

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 60,423 shs
• Average Volume: 166,586 shs
• Market Capitalization: C$2.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: TSE:TRIL
• Previous Symbol: TSE:SSS
• CIK: N/A
• Web: www.trilliumtherapeutics.com
• Phone: +1-416-5950627
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 12.04
• Quick Ratio: 11.54

Sales & Book Value

• Annual Sales: C$43 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.77
• Book Value: C$2.17 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 104,995,000
• Free Float: N/A
• Market Cap: C$2.45 billion
• Optionable: Not Optionable
• Beta: N/A